What is the 13F Pro Quality Score for GERN?

13F Pro ranks GERON CORP (GERN) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View GERN's current score at https://13fpro.ai/research/GERN (free sign-up required for the full ranking).

Which hedge funds own the most GERN stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of GERN include RA CAPITAL MANAGEMENT, L.P., BlackRock,, Soleus Capital Management, L.P.. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/GERN as soon as new 13F filings post.

Where does 13F Pro source GERN data?

All GERON CORP fundamentals and ownership data come directly from SEC EDGAR. GERON CORP files with the SEC under CIK 886744. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is GERN in?

GERON CORP (GERN) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is GERN research updated on 13F Pro?

GERN's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

GERON CORP(GERN)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 886744 GERN stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

GERN Stock Analysis & AI Quality Score

AI stock analysis and institutional research for GERON CORP (GERN), a Healthcare sector company. GERN is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), GERON CORP reports quarterly revenue of $51.8M, net income of $-3.6M, free cash flow of $-62.9M. Top institutional holders of GERN by reported 13-F value include RA CAPITAL MANAGEMENT, L.P., BlackRock,, Soleus Capital Management, L.P., based on the most recent SEC filings. GERN trades on the Nasdaq exchange and files with the SEC under CIK 886744. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate GERN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for GERON CORP directly from SEC EDGAR. GERON CORP's 13F Pro composite quality score has ranged between 14 and 32 since 2024, currently 32.4 — an improving long-term trajectory across 8 quarterly and live scoring snapshots.

Revenue

Q1 2026

$51.8M

Net Income

Q1 2026

$-3.6M

Free Cash Flow

Q1 2026

$-62.9M

D/E Ratio

Q1 2026

0.52

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

—FY 2025

FY22 $596.0KFY23 $237.0KFY24 —FY25 —

Net Income

+52.2% YoY

$-83.5MFY 2025

FY22 $-141.9MFY23 $-184.1MFY24 $-174.6MFY25 $-83.5M

Operating Income

+60.5% YoY

$-68.6MFY 2025

FY22 $-138.6MFY23 $-193.9MFY24 $-173.7MFY25 $-68.6M

EPS (Diluted)

+51.9% YoY

$-0.13FY 2025

FY22 $-0.37FY23 $-0.32FY24 $-0.27FY25 $-0.13

Total Assets

-3.9% YoY

$570.5MFY 2025

FY22 $190.6MFY23 $394.1MFY24 $593.8MFY25 $570.5M

Total Debt

+0.9% YoY

$119.5MFY 2025

FY22 $72.1MFY23 $128.8MFY24 $118.5MFY25 $119.5M

Op. Cash Flow

+49.2% YoY

$-111.0MFY 2025

FY22 $-127.4MFY23 $-167.7MFY24 $-218.6MFY25 $-111.0M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	—	—	$237.0K -60.2%	$596.0K -57.2%	$1.4M +450.6%	$253.0K
Net Income	$-83.5M +52.2%	$-174.6M +5.2%	$-184.1M -29.8%	$-141.9M -22.2%	$-116.1M -53.6%	$-75.6M
Operating Income	$-68.6M +60.5%	$-173.7M +10.4%	$-193.9M -40.0%	$-138.6M -21.5%	$-114.0M -48.2%	$-76.9M
EPS (Diluted)	$-0.13 +51.9%	$-0.27 +15.6%	$-0.32 +13.5%	$-0.37 -5.7%	$-0.35 -25.0%	$-0.28
Total Assets	$570.5M -3.9%	$593.8M +50.7%	$394.1M +106.8%	$190.6M -15.7%	$226.0M -16.5%	$270.7M
Total Debt	$119.5M +0.9%	$118.5M -8.0%	$128.8M +78.7%	$72.1M +44.7%	$49.8M +107.3%	$24.0M
Operating Cash Flow	$-111.0M +49.2%	$-218.6M -30.3%	$-167.7M -31.7%	$-127.4M -33.3%	$-95.6M -43.4%	$-66.7M

AI Insight: GERN Financial Trends

Operating losses are narrowing sharply — Q1 2026 reached breakeven op income at $0M, the best result since commercialization began.

• Operating income improved from -$69M in Q2 2024 to $0M in Q1 2026, a near-complete elimination of operating losses.

• Revenue scaled from $1M in Q2 2024 to $52M in Q1 2026, reflecting rapid commercial ramp of Rytelo.

• Total debt dropped from $165M in Q4 2024 to $120M in Q1 2026, reducing leverage meaningfully.

• Equity has eroded steadily from $307M in Q2 2024 to $229M in Q1 2026 as cumulative losses persist.

⚠ Operating cash flow deteriorated sharply to -$63M in Q1 2026 from -$14M in Q3 2025 — largest outflow in four quarters.

⚠ Net income worsened to -$29M in Q4 2025 before improving to -$4M in Q1 2026; Q4 step-back warrants monitoring for seasonality.

⚠ Revenue data missing for Q4 2024 and Q4 2025, limiting full-year trend visibility and comparability.

AI Insight: GERN Ratio Trends

GERN flips to near-breakeven in Q1 2026, with operating margin reaching 0.3% and ROIC turning positive at 0.2% — the first positive readings in the dataset.

• Operating margin surged from -99.8% in Q3 2024 to 0.3% in Q1 2026, a dramatic multi-quarter recovery toward breakeven.

• ROIC turned positive to 0.2% in Q1 2026, reversing from deeply negative readings as low as -63.5% in Q2 2024.

• ROA improved materially from -60.0% in Q2 2024 to -2.7% in Q1 2026, reflecting reduced cash burn relative to assets.

• D/E has oscillated between 0.42 and 0.59 since Q2 2024, with Q1 2026 at 0.52 — leverage broadly stable, no meaningful deleveraging.

⚠ Q4 2025 ROE spiked to -51.1% and ROIC to -29.6%, suggesting a material one-off drag — watch for recurrence in upcoming quarters.

⚠ Net profit margin remains negative at -7.0% in Q1 2026 despite near-breakeven operating margin; below-the-line costs still pressuring profitability.

⚠ Q1 2026 breakeven may reflect early commercial traction — sustainability across subsequent quarters is the key inflection to confirm.

Get alerted when GERN's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for GERON CORP including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of GERN

RA CAPITAL MANAGEMENT, L.P.
$95.0M63,771,366 sh
BlackRock, Inc.
$70.5M47,319,779 sh
Soleus Capital Management, L.P.
$61.8M41,508,659 sh
Deep Track Capital, LP
$47.3M31,720,278 sh
STATE STREET CORP
$45.4M30,497,183 sh
VANGUARD CAPITAL MANAGEMENT LLC
$39.7M26,669,029 sh
CITADEL ADVISORS LLC
$32.1M21,576,569 sh
Point72 Asset Management, L.P.
$30.5M20,457,134 sh
Clearbridge Investments, LLC
$29.2M19,620,320 sh
Eversept Partners, LP
$28.1M18,834,883 sh

Fund	Value	Shares
RA CAPITAL MANAGEMENT, L.P.	$95.0M	63,771,366
BlackRock, Inc.	$70.5M	47,319,779
Soleus Capital Management, L.P.	$61.8M	41,508,659
Deep Track Capital, LP	$47.3M	31,720,278
STATE STREET CORP	$45.4M	30,497,183
VANGUARD CAPITAL MANAGEMENT LLC	$39.7M	26,669,029
CITADEL ADVISORS LLC	$32.1M	21,576,569
Point72 Asset Management, L.P.	$30.5M	20,457,134
Clearbridge Investments, LLC	$29.2M	19,620,320
Eversept Partners, LP	$28.1M	18,834,883

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put GERN on your watchlist

Track score changes the day GERON CORP files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is GERN a good stock to buy?

13F Pro's AI-powered analysis of GERON CORP (GERN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for GERN are available on the GERN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own GERN?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling GERN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of GERON CORP's investment landscape.